immunoSCAPE is an immune profiling company with the mission to enable immunotherapy by partnering with drug development organizations. Leveraging our unique technology platforms, we provide pharmaceutical/biotechnology partners with the immune fingerprint of their clinical trial samples. Information from our high-dimensional immune profiling is used to assess alterations of immune response driven by disease or treatment, identify biomarkers that separate responders and non-responders, examine the drug's biological activity and mechanism of action and find novel targets. immunoSCAPE’s unique technology and approach leverages CyTOF, Flow, TCR Sequencing, Immune Imaging, and other platforms with the combination of proprietary reagents and sophisticated analytical tools. Providing protein-based immunological data to immunoSCAPE’s partners allows for immunological insights from samples with the goal to accelerate immunotherapy development and lower clinical trial failure rates.

Curren...
immunoSCAPE is an immune profiling company with the mission to enable immunotherapy by partnering with drug development organizations. Leveraging our unique technology platforms, we provide pharmaceutical/biotechnology partners with the immune fingerprint of their clinical trial samples. Information from our high-dimensional immune profiling is used to assess alterations of immune response driven by disease or treatment, identify biomarkers that separate responders and non-responders, examine the drug's biological activity and mechanism of action and find novel targets. immunoSCAPE’s unique technology and approach leverages CyTOF, Flow, TCR Sequencing, Immune Imaging, and other platforms with the combination of proprietary reagents and sophisticated analytical tools. Providing protein-based immunological data to immunoSCAPE’s partners allows for immunological insights from samples with the goal to accelerate immunotherapy development and lower clinical trial failure rates.

Currently, the company’s collaborators and customers include Genentech, Gilead, Macrogenics, AHRI funded by the Gates Foundation (South Africa), National Cancer Centre Singapore and MIE University (Japan). immunoSCAPE is a spin-out from A*STAR, Singapore. The US office is currently based in Boston and the company is growing to expand their presence in the US on both coasts with the addition of a CBO, business development teams and a West Coast lab.

immunoSCAPE recently closed a Series B funding led by ANZU Partners (San Diego). Other investors in Series B include: University of Tokyo Edge Capital UTEC (who led Series A) and NPR Holdings (affiliated to one of Southeast Asia's largest FMCG companies).
More information

Employees

Choon Peng Ng
Admin
Choon Peng Ng CEO Entrepreneur with extensive cross functional and cross geography experience in business management and marketing.